Proteomic Analyses of Pancreatic Cyst Fluids

Objectives: There are currently no diagnostic indicators that are consistently reliable, obtainable, and conclusive for diagnosing and risk-stratifying pancreatic cysts. Proteomic analyses were performed to explore pancreatic cyst fluids to yield effective diagnostic biomarkers. Methods: We have prospectively recruited 20 research participants and prepared their pancreatic cyst fluids specifically for proteomic analyses. Proteomic approaches applied were as follows: (1) matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry peptidomics with LC/MS/MS (HPLC-tandem mass spectrometry) protein identification; (2) 2-dimensional gel electrophoresis; (3) GeLC/MS/MS (tryptic digestion of proteins fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and identified by LC/MS/MS). Results: Sequencing of more than 350 free peptides showed that exopeptidase activities rendered peptidomics of cyst fluids unreliable; protein nicking by proteases in the cyst fluids produced hundreds of protein spots from the major proteins, making 2-dimensional gel proteomics unmanageable; GeLC/MS/MS revealed a panel of potential biomarker proteins that correlated with carcinoembryonic antigen (CEA). Conclusions: Two homologs of amylase, solubilized molecules of 4 mucins, 4 solubilized CEA-related cell adhesion molecules (CEACAMs), and 4 S100 homologs may be candidate biomarkers to facilitate future pancreatic cyst diagnosis and risk-stratification. This approach required less than 40 &mgr;L of cyst fluid per sample, offering the possibility to analyze cysts smaller than 1 cm in diameter.

[1]  C. Röcken,et al.  Proteomics of Pancreatic Cancer , 2008, Pancreas.

[2]  J. Jones,et al.  A review of the S100 proteins in cancer. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[3]  P. Tempst,et al.  A Sequence-specific Exopeptidase Activity Test (SSEAT) for “Functional” Biomarker Discovery*S , 2008, Molecular & Cellular Proteomics.

[4]  G. Dranoff,et al.  Inciting inflammation: the RAGE about tumor promotion , 2008, The Journal of experimental medicine.

[5]  Y. Gong,et al.  Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound‐guided fine‐needle aspiration specimens of the pancreas , 2007, International journal of cancer.

[6]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[7]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[8]  C. Logsdon,et al.  Progress on molecular markers of pancreatic cancer , 2007, Current opinion in gastroenterology.

[9]  C. Moskaluk,et al.  The Level of Carcinoembryonic Antigen and the Presence of Mucin as Predictors of Cystic Pancreatic Mucinous Neoplasia , 2007, Pancreas.

[10]  Tao Zhang,et al.  Searchable high-resolution 2D gel proteome of the human colon crypt. , 2007, Journal of proteome research.

[11]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[12]  C. Geczy,et al.  Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease , 2007, Scandinavian journal of gastroenterology.

[13]  M. Huddleston,et al.  A Quantitative Results-driven Approach to Analyzing Multisite Protein Phosphorylation , 2006, Molecular & Cellular Proteomics.

[14]  K. Ohuchida,et al.  S100A11, A Putative Tumor Suppressor Gene, Is Overexpressed in Pancreatic Carcinogenesis , 2006, Clinical Cancer Research.

[15]  Christof R Hauck,et al.  CEACAMs: their role in physiology and pathophysiology , 2006, Current Opinion in Cell Biology.

[16]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[17]  S. Batra,et al.  Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. , 2006, Biochimica et biophysica acta.

[18]  Kenoki Ohuchida,et al.  The Role of S100A6 in Pancreatic Cancer Development and Its Clinical Implication as a Diagnostic Marker and Therapeutic Target , 2005, Clinical Cancer Research.

[19]  M. Mann,et al.  Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein*S , 2005, Molecular & Cellular Proteomics.

[20]  K. Coombes,et al.  Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. , 2005, Journal of proteome research.

[21]  Jeffrey S. Morris,et al.  Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. , 2005, Journal of the National Cancer Institute.

[22]  Zhaohui Lu,et al.  Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue , 2004, Proteomics.

[23]  Bhavinkumar B. Patel,et al.  Analyzing alkaline proteins in human colon crypt proteome. , 2004, Journal of proteome research.

[24]  K. Lewandrowski,et al.  Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. , 2004, Gastroenterology.

[25]  H. Friess,et al.  Application of laser capture microdissection combined with two‐dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma , 2003, Proteomics.

[26]  P. Rouleau,et al.  Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.

[27]  Leif E. Peterson.  Partitioning large-sample microarray-based gene expression profiles using principal components analysis , 2003, Comput. Methods Programs Biomed..

[28]  R. Hruban,et al.  Epidemiology and risk factors , 2002 .

[29]  M. Goebeler,et al.  S100A8 and S100A9 in inflammatory diseases , 2001, The Lancet.

[30]  C. Forsmark,et al.  Cystic neoplasms of the pancreas , 2000, Current treatment options in gastroenterology.

[31]  E. Dimagno,et al.  Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms? , 2000, Annals of surgery.

[32]  W. Zimmermann,et al.  Redefined nomenclature for members of the carcinoembryonic antigen family. , 1999, Experimental cell research.

[33]  M. Talamini,et al.  Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. , 1999, The American journal of surgical pathology.

[34]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  G. Klöppel.  Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. , 1998, Hepato-gastroenterology.

[36]  V. Vilgrain,et al.  Diagnostic value of CA 72–4 and carcinoembryonic antigen determination in the fluid of pancreatic cystic lesions , 1998, European journal of gastroenterology & hepatology.

[37]  V. Vilgrain,et al.  Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas , 1997, International journal of cancer.

[38]  D. L. Sobin,et al.  Histological Typing of Tumours of the Exocrine Pancreas , 1996, World Health Organization International Histological Classification of Tumours.

[39]  V. Vilgrain,et al.  [Diagnosis of cystadenomas and cystadenocarcinomas of the pancreas. Study of 35 cases]. , 1995, Gastroenterologie clinique et biologique.

[40]  C. Yeo,et al.  Cystic and pseudocystic diseases of the pancreas. , 1994, Current problems in surgery.

[41]  C. Compton,et al.  Cyst Fluid Analysis in the Differential Diagnosis of Pancreatic Cysts A Comparison of Pseudocysts, Serous Cystadenomas, Mucinous Cystic Neoplasms, and Mucinous Cystadenocarcinoma , 1993, Annals of surgery.

[42]  Phil Gold,et al.  SPECIFIC CARCINOEMBRYONIC ANTIGENS OF THE HUMAN DIGESTIVE SYSTEM , 1965, The Journal of experimental medicine.

[43]  D. Faigel,et al.  ASGE guideline: complications of EUS. , 2005, Gastrointestinal endoscopy.

[44]  M. Sarr,et al.  Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. , 1994, American journal of surgery.